# Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea

> **NCT01832402** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 35 (actual)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** Fentanyl Pectin Nasal Spray
- **DRUG:** Placebo Nasal Spray
- **OTHER:** Walk Test
- **BEHAVIORAL:** Questionnaires
- **BEHAVIORAL:** Mental Ability Tests

## Key facts

- **NCT ID:** NCT01832402
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-11
- **Primary completion:** 2019-11-25
- **Final completion:** 2019-11-25
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01832402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01832402, "Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01832402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*